ICU Medical (NASDAQ:ICUI) VP Daniel Woolson Sells 5,417 Shares of Stock

ICU Medical, Inc. (NASDAQ:ICUI) VP Daniel Woolson sold 5,417 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total transaction of $982,264.61. Following the completion of the sale, the vice president owned 17,062 shares of the company’s stock, valued at $3,093,852.46. The trade was a 24.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

ICU Medical Price Performance

NASDAQ ICUI opened at $183.11 on Friday. ICU Medical, Inc. has a 1 year low of $111.42 and a 1 year high of $192.85. The company has a fifty day simple moving average of $155.63 and a 200 day simple moving average of $141.67. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. The company has a market cap of $4.58 billion, a P/E ratio of 155.18, a P/E/G ratio of 2.51 and a beta of 0.74.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, topping the consensus estimate of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The firm had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same quarter last year, the firm posted $2.10 EPS. The business’s quarterly revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, sell-side analysts predict that ICU Medical, Inc. will post 6.51 EPS for the current year.

Institutional Trading of ICU Medical

Hedge funds have recently modified their holdings of the company. AQR Capital Management LLC increased its position in shares of ICU Medical by 2.5% during the first quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock valued at $1,297,000 after purchasing an additional 229 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in ICU Medical by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier’s stock worth $1,772,000 after purchasing an additional 560 shares during the period. United Services Automobile Association bought a new position in ICU Medical in the first quarter worth $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in ICU Medical by 32.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier’s stock worth $9,472,000 after buying an additional 16,680 shares in the last quarter. Finally, Intech Investment Management LLC boosted its stake in ICU Medical by 38.6% during the first quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier’s stock worth $1,658,000 after buying an additional 3,326 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

Key ICU Medical News

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q2 results beat expectations. ICU Medical reported adjusted earnings of $2.37 per share, well above the $1.91 analyst consensus, while revenue of $547.88 million exceeded estimates of $533.44 million. Revenue increased modestly year over year, and the company maintained fiscal 2026 EPS guidance of $8.60 to $9.00. ICU Medical Q2 2026 Earnings Call Transcript
• Positive Sentiment: Analyst sentiment remains supportive. Following the earnings release, Needham raised its price target to $187, Piper Sandler to $195, and BTIG Research to $200, while maintaining positive ratings. Raymond James also reiterated its strong-buy rating with a $200 target. The consensus rating is “Moderate Buy,” with an average target of $192.80.
• Positive Sentiment: Investor attention remains focused on the earnings call. Analysts’ questions centered on the company’s quarterly performance and outlook, suggesting that the earnings beat and management’s commentary remain the key drivers of current trading interest. The 5 Most Interesting Analyst Questions From ICU Medical’s Q2 Earnings Call
• Neutral Sentiment: Valuation is demanding. ICU Medical trades near its 52-week high at a very elevated forward valuation, making the stock more sensitive to any slowdown in growth or signs that the recent earnings momentum cannot be sustained.
• Negative Sentiment: Several insiders sold shares. Vice President Daniel Woolson sold 5,417 shares for approximately $982,000, COO Christian Voigtlander sold 8,929 shares for about $1.63 million, CIO Ben Sousa sold 2,250 shares for $401,000, and Director Elisha Finney sold 378 shares for roughly $69,000. The transactions reduced their holdings by meaningful percentages and may raise concerns about insider conviction, although such sales can also reflect personal liquidity or diversification. ICU Medical Insider Sales

Analyst Ratings Changes

ICUI has been the topic of a number of research analyst reports. Sanford C. Bernstein lowered ICU Medical to a “market perform” rating in a report on Monday, June 15th. Wall Street Zen upgraded ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Needham & Company LLC increased their price objective on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Weiss Ratings upgraded shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Finally, Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a research note on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $192.80.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.